1. A Review of Local Therapy for the Management of Cystoid Macular Edema in Uveitis
- Author
-
Yi Hsuan Li, Shiuh-Liang Hsu, and Shwu-Jiuan Sheu
- Subjects
medicine.medical_specialty ,genetic structures ,Macular Edema ,Uveitis ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Adrenal Cortex Hormones ,medicine ,Humans ,Macular edema ,Clinical Trials as Topic ,Nonsteroidal ,business.industry ,Treatment options ,General Medicine ,medicine.disease ,Dermatology ,eye diseases ,Biologic Agents ,Discontinuation ,Clinical trial ,Ophthalmology ,chemistry ,030221 ophthalmology & optometry ,sense organs ,business ,030217 neurology & neurosurgery - Abstract
Uveitic macular edema is a significant cause of visual impairment in most uveitis types. Treatment options of uveitis have advanced remarkably in recent years. Up to now, corticosteroids remain the mainstay of treatment. Nonsteroidal immunomodulators, and recently the biologic agents, which can reinforce efficacy and enable discontinuation or reduction of steroids to maintenance doses, are becoming increasingly popular in the management of uveitic macular edema. Several medications can be used in intraocular delivery and more and more sustained releasing implants are being developed. This review will briefly focus on the review of local therapy for the management of cystoid macular edema in uveitis, as many of these novel approaches are currently being evaluated in clinical trials.
- Published
- 2021